<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804904</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3101-I-02</org_study_id>
    <nct_id>NCT04804904</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects</brief_title>
  <official_title>A Single Center, Phase I, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of TQB3101 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of food on the pharmacokinetics of TQB3101 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dosing on Day 1 up to 144 hours post-dosing</time_frame>
    <description>maximum concentration of the analyte in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>pre-dosing on Day 1 up to 144 hours post-dosing</time_frame>
    <description>Time to Reach the Maximum Observed Plasma Concentration (Cmax) of the analyte</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>pre-dosing on Day 1 up to 144 hours post-dosing</time_frame>
    <description>Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of the analyte</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>pre-dosing on Day 1 up to 144 hours post-dosing</time_frame>
    <description>Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time of the analyte</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pharmacokinetic Study</condition>
  <arm_group>
    <arm_group_label>TQ-B3101: Fed + Fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQ-B3101: Fast+Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3101</intervention_name>
    <description>TQ-B3101 oral capsule</description>
    <arm_group_label>TQ-B3101: Fast+Fed</arm_group_label>
    <arm_group_label>TQ-B3101: Fed + Fast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be willing and able to give written informed consent by signing an&#xD;
             IRB-approved Informed Consent Form prior to admission to this study;&#xD;
&#xD;
          -  Subjects must be willing and able to communicate well, understand and follow the&#xD;
             protocol required to complete the study;&#xD;
&#xD;
          -  Males and females between 18 to 60 years of age&#xD;
&#xD;
          -  Males and females with a body mass Index (BMI) range 19~26 kg/m2 inclusive, male&#xD;
             subject not less than 50kg, female subject not less than 45kg。&#xD;
&#xD;
          -  Male subjects must agree to use a medically acceptable method of contraception from&#xD;
             Screening until 6 months after administration of the last dose of study drug&#xD;
&#xD;
          -  Male subjects agrees not to donate sperm for at least 6 months after administration of&#xD;
             the last dose of study drug&#xD;
&#xD;
          -  Female subjects of non-childbearing potential measures, meeting at least one of the&#xD;
             following criteria:①menorrhoeal for 12 months and FSH &gt;40mIU/mL;②&#xD;
             hysterectomy;③oophorectomy.&#xD;
&#xD;
          -  Subjects who are healthy as determined by physical examination,vital signs, 12-Lead&#xD;
             ECG and X-ray examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a history or presence of cardiovascular, neurological, endocrine,&#xD;
             respiratory, hematological, immunological, psychiatric diseases or disorders that,&#xD;
             could affect the conduct of the study or the absorption, metabolism or excretion of&#xD;
             the study drug.&#xD;
&#xD;
          -  Subjects who have a history of relevant drug hypersensitivity or atopic allergic&#xD;
             disease history(asthma,urticaria, eczema dermatitis).&#xD;
&#xD;
          -  Current or recent (within 6 months of study drug administration) gastrointestinal ,&#xD;
             liver and kidney disease that could impact upon the absorption of study drug.&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration .&#xD;
&#xD;
          -  Subjects who consume more than 14 units of alcohol per week during 3 months before&#xD;
             drug administration, taken any alcohol-containing products within 24 hours ,or&#xD;
             subjects who test negative alcohol at screening and admission&#xD;
&#xD;
          -  Smokers who smoked more than 5 cigarettes before study drug administration,or can not&#xD;
             quit smoking during the study.&#xD;
&#xD;
          -  Subjects who test positive for drugs of abuse.&#xD;
&#xD;
          -  Subjects who have donated blood or have a blood loss(≥300mL)within the previous 3&#xD;
             months prior to first dosing.&#xD;
&#xD;
          -  Subjects who used any drugs that change liver enzyme activity,such as inhibitors or&#xD;
             inducers of CYP3A4, P-gp or BCRP within 28days;&#xD;
&#xD;
          -  Subjects who used any drugs including over thePrescription drugs, counter medications&#xD;
             ,vitamin products herbal preparations.&#xD;
&#xD;
          -  Subjects who have taken a special diet (including grapefruit, etc.) or exercised&#xD;
             vigorously in the 14 days ,or other factors affecting drug absorption, distribution,&#xD;
             metabolism, and excretion&#xD;
&#xD;
          -  Participated in drug clinical trials within 3 months before taking the study ;&#xD;
&#xD;
          -  Subjects with laboratory abnormalities,or or white blood cell count, neutrophil cell&#xD;
             count and the percentage of the platelet count below the normal limit.&#xD;
&#xD;
          -  Positive test result for HIV antibodies.&#xD;
&#xD;
          -  Positive test for treponema Antibodies hepatitis B surface antigen (HBsAg), hepatitis&#xD;
             C virus antibody (HCV Ab).&#xD;
&#xD;
          -  Subjects who have acute disease or concomitant medication at the time of screening&#xD;
             and/or admission.&#xD;
&#xD;
          -  Subjects who consuming chocolate, any caffeine-rich or xanthine-rich food or drink 24&#xD;
             hours before.&#xD;
&#xD;
          -  The PI considered other factors unfit to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongrong Xu, PhD</last_name>
    <phone>+86-13651893721</phone>
    <email>xu.hongrong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongrong Xu, PhD</last_name>
      <phone>+86-13651893721</phone>
      <email>xu.hongrong@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

